Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Liabilities and Shareholders Equity (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $45.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 39.89% to $45.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $230.5 million through Dec 2025, down 27.34% year-over-year, with the annual reading at $45.9 million for FY2025, 39.89% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $45.9 million at Mereo BioPharma, down from $53.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $170.4 million in Q4 2021, with the low at $45.9 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $78.4 million, with a median of $68.3 million recorded in 2025.
  • The sharpest move saw Liabilities and Shareholders Equity surged 105.02% in 2021, then crashed 54.57% in 2022.
  • Over 5 years, Liabilities and Shareholders Equity stood at $170.4 million in 2021, then plummeted by 54.57% to $77.4 million in 2022, then dropped by 14.1% to $66.5 million in 2023, then rose by 14.87% to $76.4 million in 2024, then tumbled by 39.89% to $45.9 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $45.9 million, $53.6 million, and $62.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.